On the 15 minute chart, PLUG got a deserving bad haircut today on the dilution announcement.
Buying shares in a chas burning enterprise is risky business. However, the prospects of
a rescue with a federal grant from the Green Left initiative can come any time. Shares
are on sale. So are OTM call options expiring after the recovery if there is one. Price...
Meet Julia, She's been trying hard to get into college, and she finally got in, sad part is her family does NOT have enough to pay for her college tuitions.
There's only so far I can go in helping her as an individual...
I decided to ask the Public to help in her aid!
Here's the USDT ADDRESS:
TRC20; TL2QbgdAERJRc6KXCsT5viKCG72p9PsPNq
Make it count!🎯
Surgalign Holdings Inc is a medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient's lives. It markets products throughout the United...
Document Security Systems Inc operates in the security and commercial printing, packaging and plastic ID markets. The company develops, markets, manufactures and sells paper and plastic products designed to protect valuable information from unauthorized scanning, copying, and digital imaging. It is organized into the operating segments of Packaging and Printing;...
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
$NSPR today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering...
Price collapsed due to Public Offering
Huge investment on the company (24M$)
Previous earnings were positive, growing business
4$ is a GREAT price
Multiweek / Multimonth depending on TP
SELLAS intends to use the net proceeds from the offering to commence a pivotal Phase 3 trial for its lead clinical candidate, galinpepimut-S (“GPS”), as a monotherapy in acute myeloid leukemia patients following second complete remission and to continue its Phase 1/2 basket type trial of GPS in combination with pembrolizumab, as well as for general corporate...
